



US005510383A

United States Patent [19]**Bishop et al.**[11] **Patent Number:** **5,510,383**[45] **Date of Patent:** **Apr. 23, 1996**

[54] **USE OF CLOPROSTENOL, FLUPROSTENOL AND THEIR SALTS AND ESTERS TO TREAT GLAUCOMA AND OCULAR HYPERTENSION**

[75] Inventors: **John E. Bishop**, Arlington; **Louis DeSantis, Jr.**, Fort Worth; **Verney L. Sallee**, Burleson, all of Tex.

[73] Assignee: **Alcon Laboratories, Inc.**, Fort Worth, Tex.

[21] Appl. No.: **101,598**

[22] Filed: **Aug. 3, 1993**

[51] Int. Cl.⁶ **A61K 31/557**

[52] U.S. Cl. **514/530; 514/573**

[58] Field of Search **514/530, 573**

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,599,353	7/1986	Bito	514/530
5,288,754	2/1994	Woodward et al.	514/530
5,352,708	10/1994	Woodward et al.	514/729

FOREIGN PATENT DOCUMENTS

330511A2	8/1989	European Pat. Off. .
364417A1	4/1990	European Pat. Off. .
435682A2	7/1991	European Pat. Off. .
90/02553	3/1990	WIPO .

OTHER PUBLICATIONS

Coleman et al., "Prostanoids and their Receptors," *Comprehensive Medicinal Chemistry*, vol. 3 (1990), 12.1:643-714.
Narumiya et al., "Structure and function of prostanoid

receptors," *J. of Lipid Mediators*, 6:155-161 (1993).

Woodward et al., "Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies," *J. of Lipid Mediators*, 6:545-553 (1993).

Bito et al., "The ocular effects of prostaglandins and the therapeutic potential of a new PGF_{2α} analog, PhXA41 (latanoprost), for glaucoma management," *J. of Lipid Mediators*, 6:535-543 (1993).

Resul et al., "Phenyl-Substituted Prostaglandins: Potent and Selective Antiglaucoma Agents," *J. Med. Chem.*, 36:243-248 (1993).

Stjernschantz et al., "Phenyl substituted prostaglandin analogs for glaucoma treatment," *Drugs of the Future*, 17(8):691-704 (1992).

The Merck Index, 11th Ed., p. 375 (1989).

Zajacz et al., "Effect on Human Eye of Prostaglandin and a Prostaglandin Analogue Used to Induce Abortion," *IRCS Medical Science: Clinical Medicine: Clinical Pharmacology & Therapeutics: Drug Metabolism & Toxicology: The Eye: Reproduction, Obstetrics & Gynecology*, 4:316 (1976).
The Merck Index, 11th Ed., pp. 656-657 (1989).

Primary Examiner—Richard L. Raymond

Attorney, Agent, or Firm—James A. Arno; Barry L. Copeland; Julie J. L. Cheng

[57] **ABSTRACT**

Disclosed is the use of cloprostenol, fluprostenol, and their pharmaceutically acceptable salts and esters for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.

20 Claims, 3 Drawing Sheets